Predicting outcomes in acute severe ulcerative colitis

References

• Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010;4:431-7
   PubMed Web of Science ®Google Scholar
• Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963;4:299-315
   PubMed Web of Science ®Google Scholar
• Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007;5:103-10
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-8
   PubMed Web of Science ®Google Scholar
• Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-90
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23; quiz 524
   PubMed Web of Science ®Google Scholar
• Brown SR, Haboubi N, Hampton J, et al. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis 2008;10(Suppl 3):8-29
   PubMed Web of Science ®Google Scholar
• Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345-51
   PubMed Web of Science ®Google Scholar
• Olaisen M, Rydning A, Martinsen TC, et al. Cytomegalovirus infection and postoperative complications in patients with ulcerative colitis undergoing colectomy. Scand J Gastroenterol 2014;49:845-52
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Yoshida Y. What are the factors that affect hospitalization and surgery for aggravation of ulcerative colitis? Eur J Gastroenterol Hepatol 2014;26:282-7
   PubMed Web of Science ®Google Scholar
• Kopylov U, Eliakim-Raz N, Szilagy A, et al. Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis. World J Gastroenterol 2014;20:2695-703
   PubMed Web of Science ®Google Scholar
• De Silva S, Ma C, Proulx M-C, et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:972-80
   PubMed Web of Science ®Google Scholar
• Kaplan GG, McCarthy EP, Ayanian JZ, et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008;134:680-7
   PubMed Web of Science ®Google Scholar
• Randall J, Singh B, Warren BF, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010;97:404-9
   PubMed Web of Science ®Google Scholar
• Bojic D, Radojicic Z, Nedeljkovic-Protic M, et al. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Inflamm Bowel Dis 2009;15:823-8
   PubMed Web of Science ®Google Scholar
• Bewtra M, Kaiser LM, TenHave T, et al. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013;19:599-613
   PubMed Web of Science ®Google Scholar
• Roberts SE, Williams JG, Yeates D, et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies. BMJ 2007;335:1033
   PubMedGoogle Scholar
• Nicholls RJ, Clark DN, Kelso L, et al. Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis. Aliment Pharmacol Ther 2010;31:1310-21
   PubMed Web of Science ®Google Scholar
• Ventham NT, Kennedy NA, Duffy A, et al. Comparison of mortality following hospitalisation for ulcerative colitis in Scotland between 1998-2000 and 2007-2009. Aliment Pharmacol Ther 2014;39:1387-97
   PubMed Web of Science ®Google Scholar
• Lynch RW, Lowe D, Protheroe A, et al. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther 2013;38:935-45
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Ritchie JK, Hilder W, et al. Assessment of severity in colitis: a preliminary study. Gut 1975;16:579-84
   PubMed Web of Science ®Google Scholar
• Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10
   PubMed Web of Science ®Google Scholar
• Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-5
   PubMed Web of Science ®Google Scholar
• Ho GT, Mowat C, Goddard CJR, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19:1079-87
   PubMed Web of Science ®Google Scholar
• Churchhouse AM, Lynch RW, Protheroe A, et al. P168 Predicting outcome in acute ulcerative colitis: comparison of the Travis and Ho scores using UK IBD Audit data. J Crohn’s Colitis 2014;8:S132
   Google Scholar
• Kennedy N, Van Ross JE, Hare NC, et al. Acute severe ulcerative colitis: the last 12 years in Edinburgh. Gut 2012;61:A235-6
   PubMed Web of Science ®Google Scholar
• Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971-6
   PubMed Web of Science ®Google Scholar
• Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11
   PubMed Web of Science ®Google Scholar
• D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86
   PubMed Web of Science ®Google Scholar
• Carbonnel F, Gargouri D, Lémann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000;14:273-9
   PubMed Web of Science ®Google Scholar
• Daperno M, Sostegni R, Scaglione N, et al. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis 2004;36:21-8
   PubMedGoogle Scholar
• Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32
   PubMed Web of Science ®Google Scholar
• Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008;57:331-8
   PubMed Web of Science ®Google Scholar
• Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282-91
   PubMed Web of Science ®Google Scholar
• Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010;59:1207-12
   PubMed Web of Science ®Google Scholar
• Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673-8
   PubMed Web of Science ®Google Scholar
• Hare NC, Kennedy NA, Kalla R, et al. P349 Serum calprotectin: a novel biomarker to predict outcome in acute severe ulcerative colitis? J Crohn’s Colitis 2014;8:S210
   Google Scholar
• Chew CN, Nolan DJ, Jewell DP. Small bowel gas in severe ulcerative colitis. Gut 1991;32:1535-7
   PubMed Web of Science ®Google Scholar
• Ordás I, Rimola J, García-Bosch O, et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut 2013;62:1566-72
   PubMed Web of Science ®Google Scholar
• Hafeez R, Punwani S, Pendse D, et al. Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitis-a preliminary study. Eur Radiol 2011;21:366-77
   PubMed Web of Science ®Google Scholar
• Da Luz Moreira A, Vogel JD, Baker M, et al. Does CT influence the decision to perform colectomy in patients with severe ulcerative colitis? J Gastrointest Surg 2009;13:504-7
   PubMed Web of Science ®Google Scholar
• Almer S, Bodemar G, Franzén L, et al. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet 1996;347:1731-5
   PubMed Web of Science ®Google Scholar
• Bennink RJ, Peeters M, Rutgeerts P, et al. Evaluation of early treatment response and predicting the need for colectomy in active ulcerative colitis with 99mTc-HMPAO white blood cell scintigraphy. J Nucl Med 2004;45:1698-704
   PubMed Web of Science ®Google Scholar
• Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in Proctocolitis. Br Med J 1964;1:89-92
   PubMed Web of Science ®Google Scholar
• Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42
   PubMed Web of Science ®Google Scholar
• Carbonnel F, Lavergne A, Lémann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39:1550-7
   PubMed Web of Science ®Google Scholar
• Travis SPL, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013;145:987-95
   PubMed Web of Science ®Google Scholar
• Corte CJ, Fernandopulle AN, Catuneanu A, et al. 554 correlation between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. Gastroenterology 2013;144:S-102
   PubMed Web of Science ®Google Scholar
• Tanaka M, Saito H, Kusumi T, et al. Biopsy pathology predicts patients with ulcerative colitis subsequently requiring surgery. Scand J Gastroenterol 2002;37:200-5
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kusumi T, Oshitani N, et al. Validity of simple mucosal biopsy criteria combined with endoscopy predicting patients with ulcerative colitis ultimately requiring surgery: a multicenter study. Scand J Gastroenterol 2003;38:594-8
   PubMed Web of Science ®Google Scholar
• Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol 2011;106:2001-8
   PubMed Web of Science ®Google Scholar
• Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-17
   PubMed Web of Science ®Google Scholar
• Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997;112:1845-53
   PubMed Web of Science ®Google Scholar
• Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 2003;62:527-35
   PubMedGoogle Scholar
• Yamamoto-Furusho JK, Rodríguez-Bores L, Granados J. HLA-DRB1 alleles are associated with the clinical course of disease and steroid dependence in Mexican patients with ulcerative colitis. Colorectal Dis 2010;12:1231-5
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Kinouchi Y, Nomura E, et al. HLA-DRB1 alleles influence clinical phenotypes in Japanese patients with ulcerative colitis. Tissue Antigens 2008;71:447-52
   PubMedGoogle Scholar
• Ho G-T, Soranzo N, Nimmo ER, et al. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 2006;15:797-805
   PubMed Web of Science ®Google Scholar
• Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 2010;16:1830-40
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;490:119-24
   Google Scholar
• Gerich ME, McGovern DPB. Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol 2014;11:287-99
   PubMed Web of Science ®Google Scholar
• Roberts RL, Barclay ML. Current relevance of pharmacogenetics in immunomodulation treatment for Crohn’s disease. J Gastroenterol Hepatol 2012;27:1546-54
   PubMed Web of Science ®Google Scholar
• Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014;46(10):1131-4
   PubMed Web of Science ®Google Scholar
• Lee JC, Lyons PA, McKinney EF, et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011;121:4170-9
   PubMed Web of Science ®Google Scholar
• Kabakchiev B, Turner D, Hyams J, et al. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS One 2010;5:1-8
   Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014;15:382-92
   PubMed Web of Science ®Google Scholar
• Michail S, Durbin M, Turner D, et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis 2012;18:1799-808
   PubMed Web of Science ®Google Scholar
• Ooi M, Nishiumi S, Yoshie T, et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res 2011;60:831-40
   PubMed Web of Science ®Google Scholar
• Schicho R, Shaykhutdinov R, Ngo J, et al. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res 2012;11:3344-57
   PubMed Web of Science ®Google Scholar
• Stephens NS, Siffledeen J, Su X, et al. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J Crohns Colitis 2013;7:e42-8
   PubMedGoogle Scholar
• Miyahara K, Nouso K, Saito S, et al. Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis. PLoS One 2013;8:e74861
   PubMed Web of Science ®Google Scholar
• Theodoratou E, Campbell H, Ventham NT, et al. The role of glycosylation in IBD. Nat Rev Gastroenterol Hepatol 2014;11(10):588-600
   PubMed Web of Science ®Google Scholar
• Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013;145:293-308
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Targan SR, Dubinsky MC, et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn’s disease behavior. Inflamm Bowel Dis 2011;17:2488-96
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Kugathasan S, Kwon S, et al. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn’s disease. Inflamm Bowel Dis 2013;19:1662-70
   PubMed Web of Science ®Google Scholar
• Saito K, Katsuno T, Nakagawa T, et al. Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Aliment Pharmacol Ther 2012;36:744-54
   PubMed Web of Science ®Google Scholar
• Ríos JWH, Jordá FC, Benaprés JRM. Predictive factors of poor response to intravenous cyclosporine in steroid-refractory ulcerative colitis. 2009;101:163-71
   Google Scholar
• Cacheux W, Seksik P, Lemann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008;103:637-42
   PubMed Web of Science ®Google Scholar
• Rowe FA, Walker JH, Ph D, et al. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000;95:2000-8
   PubMed Web of Science ®Google Scholar
• Aceituno M, García-Planella E, Heredia C, et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008;14:347-52
   PubMed Web of Science ®Google Scholar
• Sjöberg M, Magnuson A, Björk J, et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013;38:377-87
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-15
   PubMed Web of Science ®Google Scholar
• Mocciaro F, Renna S, Orlando A, et al. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis 2012;6:681-6
   PubMed Web of Science ®Google Scholar
• Monterubbianesi R, Aratari A, Armuzzi A, et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis 2014;8:852-8
   PubMed Web of Science ®Google Scholar
• Mortensen C, Caspersen S, Christensen NL, et al. Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. J Crohns Colitis 2011;5:28-33
   PubMed Web of Science ®Google Scholar
• Seo M, Okada M, Yao T, et al. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002;29-34
   PubMedGoogle Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5
   PubMed Web of Science ®Google Scholar
• Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26:411-19
   PubMed Web of Science ®Google Scholar
• Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26:747-56
   PubMed Web of Science ®Google Scholar